Marinus Pharmaceuticals (NASDAQ:MRNS) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS - Free Report) from a sell rating to a hold rating in a research note released on Wednesday.

A number of other analysts have also issued reports on the stock. HC Wainwright reiterated a buy rating and set a $11.00 price objective on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. Truist Financial reaffirmed a buy rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. LADENBURG THALM/SH SH cut shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a research report on Wednesday, August 14th. Finally, Cantor Fitzgerald restated an overweight rating and set a $13.00 target price on shares of Marinus Pharmaceuticals in a research note on Monday. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Marinus Pharmaceuticals presently has a consensus rating of Hold and an average target price of $10.25.

Marinus Pharmaceuticals Trading Down 2.6 %

Shares of Marinus Pharmaceuticals stock traded down $0.04 during trading hours on Wednesday, hitting $1.51. The company's stock had a trading volume of 223,981 shares, compared to its average volume of 1,128,248. The company has a quick ratio of 2.15, a current ratio of 2.28 and a debt-to-equity ratio of 5.68. The company has a market capitalization of $82.95 million, a PE ratio of -0.57 and a beta of 1.13. The business has a fifty day moving average of $1.37 and a 200 day moving average of $2.93. Marinus Pharmaceuticals has a 1-year low of $1.05 and a 1-year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The company had revenue of $8.06 million during the quarter, compared to analysts' expectations of $9.05 million. During the same period last year, the business earned ($0.61) earnings per share. As a group, equities analysts forecast that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several large investors have recently modified their holdings of MRNS. Point72 DIFC Ltd bought a new position in shares of Marinus Pharmaceuticals during the second quarter worth about $28,000. SG Americas Securities LLC bought a new position in shares of Marinus Pharmaceuticals during the second quarter worth about $34,000. AQR Capital Management LLC lifted its position in shares of Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Marinus Pharmaceuticals during the second quarter worth about $64,000. Finally, Values First Advisors Inc. lifted its position in shares of Marinus Pharmaceuticals by 501.8% during the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company's stock worth $73,000 after purchasing an additional 52,257 shares during the last quarter. Institutional investors own 98.80% of the company's stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.